Co-Authors
This is a "connection" page, showing publications co-authored by RONALD S WALTERS and AMAN U BUZDAR.
Connection Strength
0.451
-
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
Score: 0.103
-
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
Score: 0.052
-
Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6.
Score: 0.029
-
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81.
Score: 0.026
-
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82.
Score: 0.025
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.025
-
Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol. 1990; 13 Suppl 1:S54-6.
Score: 0.022
-
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21.
Score: 0.021
-
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15; 22(12):2294-302.
Score: 0.015
-
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23.
Score: 0.014
-
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002 Jan-Feb; 8(1):2-9.
Score: 0.013
-
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
Score: 0.012
-
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
Score: 0.012
-
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
Score: 0.011
-
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
Score: 0.011
-
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
Score: 0.011
-
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21.
Score: 0.009
-
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8.
Score: 0.009
-
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94.
Score: 0.008
-
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7.
Score: 0.008
-
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
Score: 0.007
-
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18; 83(24):1797-805.
Score: 0.006